BE-101

N/A

Report date: 2024/06/14 10:54:03
First In Class

Base Information

Drug NameBE-101
Drug Alias NameBE-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > B-lymphocyte cell therapy
Mechanisms of ActionCoagulation factor IX replacements
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBe Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesBe Biopharma Inc
Inactive CompaniesN/A
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A